The CD4/CD8 T-cell ratio is emerging as a relevant marker of evolution for different pathologies and therapies, including cardiovascular diseases [1], human immunodeficiency virus (HIV) infection [2, 3], and cancer [4, 5]. This evidence concerns the gene CD8A and cancer.